Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Marco Guelfi"'
Autor:
Martinus Richter MD, PhD, Per-Henrik Agren MD, Jean-Luc Besse MD, PhD, Maria Cöster MD, Hakon Kofoed MD, Nicola Maffulli MD, MS, FRCS, PhD, Dieter Rosenbaum, Martijn Steultjens, Fernando Alvarez MD, Andrzej Boszczyk MD, PhD, Kristian Buedts MD, Marco Guelfi MD, Henryk Liszka, Jan-Willem Louwerens MD, Jussi P. Repo MD, PhD, Elena Samaila MD, Michael Stephens MD, MSc, FRCSI, Angelique G. H. Witteveen MD
Publikováno v:
Foot & Ankle Orthopaedics, Vol 4 (2019)
Category: Basic Sciences/Biologics Introduction/Purpose: A scientifically sound validated foot and ankle specific outcome measure for different European languages is still missing. Indeed, language-specific cross cultural validation in other language
Externí odkaz:
https://doaj.org/article/6a167614c7f144e5b2375818507684f8
Autor:
Anna-Rita Renzetti, A. Lippi, Marco Guelfi, Paola Cucchi, Marco Criscuoli, Carlo Alberto Maggi, R.-M. Catalioto, Laura Quartara
Publikováno v:
Biochemical and Biophysical Research Communications. 248:78-82
[ 3 H]MEN 11420, a radiolabeled glycosylated peptide antagonist of the tachykinin NK 2 receptor, has been investigated in ligand-receptor binding assays using membranes of CHO cells transfected with the human tachykinin NK 2 receptor. [ 3 H]MEN 11420
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91ffa1e70f2ee17b6fa4b9f67e72c7d2
https://doi.org/10.1006/bbrc.1998.8883
https://doi.org/10.1006/bbrc.1998.8883
Autor:
Paola Cucchi, A. Castellucci, Marco Guelfi, Stefano Evangelista, R. Cirillo, Alessandro Subissi, Antonio Giachetti, Anna Rita Renzetti, S. Caliari, A. Salimbeni
Publikováno v:
British Journal of Pharmacology. 114:1117-1124
1 The pharmacological profile of LR-B/081, (methyl 2-[[4-butyl-2-methyl-6-oxo-5-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1(6H)-pyrimidinyl]methyl]-3-thiophenecarboxylate), a novel antagonist at the angiotensin II (AII) AT1-receptor, wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b281ee9fe1d0d01fef444a7ce0b6411f
https://doi.org/10.1111/j.1476-5381.1995.tb13323.x
https://doi.org/10.1111/j.1476-5381.1995.tb13323.x
Autor:
L. Nogarin, John J. O'Connor, Leo Massari, Fabio Catani, Arturo Rebeccato, Matteo Romagnoli, Sandro Giannini, Marco Guelfi, Luigi Milano, Antonio Volpe, Alberto Leardini, Bruno Magnan, Francesco Malerba
A new design for a 3-part ankle replacement was developed in an effort to achieve compatibility with the naturally occurring ligaments of the ankle by allowing certain fibers to remain isometric during passive motion. In order to test the design conc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a5315708cfb08ee04cb7a4181e4720c
https://hdl.handle.net/11380/701538
https://hdl.handle.net/11380/701538
Autor:
Marco Criscuoli, Manuela Tramontana, Sandro Giuliani, Magali Toulouse, Marco Guelfi, Lionel Bueno, Alessandro Lecci, Carlo Alberto Maggi
Publikováno v:
European Journal of Pharmacology
European Journal of Pharmacology, Elsevier, 2001, 415, pp.61-71
European Journal of Pharmacology, Elsevier, 2001, 415, pp.61-71
The effect of the tachykinin NK(2) receptor antagonist, nepadutant (MEN 11420 or (c[[(beta-D-GlcNAc)Asn-Asp-Trp-Phe-Dpr-Leu]c(2beta-5beta)])) was assessed on cardiovascular function (unanaesthetized rats and anaesthetized dogs) and gastrointestinal m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21fb6a1c00c38d6b52da64a40ad86ac7
https://hal.inrae.fr/hal-02674575
https://hal.inrae.fr/hal-02674575
Autor:
Alessandro Subissi, Marco Guelfi, Paola Cucchi, Rocco Cirillo, Antonio Giachetti, Aldo Salimbeni, Anna Rita Renzetti
Publikováno v:
Journal of cardiovascular pharmacology. 25(3)
We studied the pharmacologic properties of LR-B/057, a novel nonpeptide angiotensin II (AII) receptor antagonist. The compound potently displaced [ 3 H]AII from AT, but not from AT 2 receptors in rat adrenal cortex (K i 3 nM), but did not modify the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa84e28b5bfde124c22fee5d1b6e5b74
https://pubmed.ncbi.nlm.nih.gov/7769798
https://pubmed.ncbi.nlm.nih.gov/7769798
Publikováno v:
Journal of cardiovascular pharmacology. 20(1)
Summary: Idrapril is the prototype of a new chemical class of angiotensin converting enzyme (ACE) inhibitors, the hydroxamic non-amino acid derivatives. Idrapril strongly inhibited rat and human plasma ACE and rabbit lung ACE (IC50: 7–12 nM) as wel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7234661ad1ba90aaba7a610f4ab4158b
https://pubmed.ncbi.nlm.nih.gov/1383623
https://pubmed.ncbi.nlm.nih.gov/1383623
Publikováno v:
British journal of pharmacology. 100(3)
1. The effects of intravenous captopril and enalaprilic acid on the increase in pulmonary inflation pressure induced by different bronchoconstrictor agents were evaluated in the anaesthetized guinea-pig. 2. Captopril and enalaprilic acid (1.6-200 mic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c65cbcc024ced2e2bee8f2513ea1d09d
https://pubmed.ncbi.nlm.nih.gov/1697196
https://pubmed.ncbi.nlm.nih.gov/1697196